Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Momelotinib in Myelofibrosis
NCT01236638Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by GSK. Primary endpoints: Long term safety and tolerability and Long term effectiveness. Started Nov 2010; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01236638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236638.